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The  importance  of  the  endoscopic  evaluation  in inflammatory  bowel  disease  (IBD)  management  has
been recognized  for many  years.  However,  the modalities  for  reporting  endoscopic  activity  represent  an
ongoing  challenge.  To  address  this,  several  endoscopic  scores  have  been  proposed.  Very  few have  been
properly  validated,  and  the  use of such  tools  remains  sub-optimal  and  is  mainly  restricted  to  clinical
trials.  In  recent  years,  a growing  emphasis  of  the  concept  of ‘mucosal  healing’  as  a  prognostic  marker
and  therapeutic  goal has  increased  the  need  for a more  accurate  definition  of endoscopic  activity  in bothndoscopic score
nflammatory bowel disease
ucosal healing
lcerative colitis
ulcerative  colitis  (UC)  and  Crohn’s  Disease  (CD).  In the  present  review,  the evolution  of  the  challenges
related  to endoscopic  scores  in  IBD  has been  analyzed,  with  particular  attention  paid  to the  renewed
relevance  of  endoscopic  activity  in recent  years.  Currently,  despite  the  growing  relevance  of  endoscopic
activity,  evaluating  this activity  in  IBD is still a challenge.  The  implementation  of  efficacious  endoscopic
scores  and  a better  definition  of the  absence  of  activity  (mucosal  healing)  are needed.
 Gast©  2016  Editrice
. Introduction
Inflammatory bowel disease (IBD) is a pathologic condition that
auses chronic inflammation and may  involve several tracts of the
ntestine. The relevance of the endoscopic evaluation in the man-
gement of IBD for diagnosis and follow-up is indisputable. This is
articularly true for ulcerative colitis (UC), which is characterized
y a mucosal inflammation that does not cross the lamina propria
nd that involves only the colon to varying degrees [1]. By contrast,
n Crohn’s Disease (CD) the inflammation is typically transmural
nd may  involve several intestinal tracts, including areas not easily
ccessible by an endoscope [2].
Several scores for the evaluation of endoscopic activity in IBD
ave been proposed. Although the first attempts to establish a
umeric score to evaluate the endoscopic activity of UC date back
o the 1950s, the challenge of correctly interpreting and codify-
ng endoscopic features has not been solved, and the issue has
ecome more important over the last decade. The wider utiliza-
ion of potent therapeutic options for IBD patients, such as biologic
rugs, has led to a consistent conceptual modification of the clinical
∗ Corresponding author at: “Sapienza” University of Rome, S. Andrea Hospital, Via
i  Grottarossa 1035, 00189 Rome, Italy. Tel.: +39 0633779; fax: +39 06 33776601.
E-mail address: cristiano.pagnini@uniroma1.it (C. Pagnini).
ttp://dx.doi.org/10.1016/j.dld.2016.03.006
590-8658/© 2016 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. Allroenterologica  Italiana  S.r.l.  Published  by Elsevier  Ltd.  All  rights  reserved.
management, with a subsequent need for the identification of new
end-points for the evaluation of therapeutic efficacy. This process
has helped move endoscopic activity evaluation toward the more
stringent concept of ‘mucosal healing’ (MH). In fact, a growing body
of evidence suggests that the complete resolution of evident signs
of inflammation during an endoscopic examination is associated
with a better long-term outcome in terms of shorter hospital stays,
an increase in sustained remission, and a decrease in the need for
surgery [3]. The evidence for and limitations of the MH  concept
are still matter of debate in the literature [4] and are beyond the
scope of the present paper. However, MH’s growing relevance in
the management of IBD has definitely influenced the challenges of
endoscopic evaluation of disease activity.
Although different diseases have different issues, on a funda-
mental level an endoscopic score is needed to codify the different
grades of intestinal disease activity observed during an endoscopic
examination in a quantitative, simple, reproducible, and acceptable
way. An early issue in the development of a scoring system has
been the identification of high-risk lesions that are easily recogniz-
able during an endoscopy. In addition, the increased complexity of
the evaluation has led to growing disagreement between different
operators (inter-observer variability) and even in repeated evalua-
tions by the same operator (intra-observer variability). It is crucial
to develop a score that will reduce such variation and standard-
ize the interpretation of results in both trials and clinical practice
 rights reserved.
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5]. The gradual shift from a symptom-based to a mucosal-based
pproach for IBD has led to new interest in the issue of endoscopic
cores and reconsideration of the finality of the score itself. There
as been a transition from the target to the gradation of endoscopic
everity and therefore to the discrimination of patients based on
isease severity and identification of the subset of patients meet-
ng the MH  criteria, despite MH’s variable definition. Such attempts
annot be finalized because no clear definition has been stated for
H in either UC or CD. For the latter disease, clinical trials generally
efer to the absence of ulcer, while for UC, most trials refer to a Mayo
ndoscopic score of 0-1 [6]. The lack of a validated cut-off for endo-
copic scores in CD and the limitation of the current Mayo definition
f 0-1 in UC further confirm that MH is yet to be clearly defined. In
C in particular, the current belief that endoscopic score of 0 and 1
ave the same prognostic relevance has recently been challenged
7,8], and the finding of a relatively higher number of patients with
ndoscopic healing, as previously defined, than with clinical remis-
ion in some trials, such as ULTRA and PURSUIT [9,10], has raised
dditional questions about the definition of MH.  Currently, primary
nd-points in clinical trials are still represented by clinical param-
ters and composite indexes, including symptoms, signs and lab
ests. The scarce applicability of such parameters in clinical practice
s decisively pushing toward the identification and better clarifica-
ion of appropriate new end-points, and among these, endoscopic
isease activity evaluation is one objective parameter that should
e included [11].
The relevance of a correct evaluation of disease activity and
f agreement among operators has been strongly reinforced by a
ecent observation that different evaluations of endoscopic reports,
uch as the evaluation by a ‘central reader’, may  profoundly alter the
eport of a trial. In a randomized, double-blind, placebo-controlled,
ulticenter study investigating the safety and efficacy of a delayed-
eleased mesalamine formulation in UC patients, the primary
nd-point of clinical remission at week 6 was not achieved in the
riginal intention-to-treat analysis (30 vs. 20.6% in the treated vs.
lacebo group, p = 0.069). Instead, it was observed after a central
eading revision by seven expert readers who independently ana-
yzed sigmoidoscopy recordings (29 vs. 13.8% in the treated vs.
lacebo group, p = 0.011) and excluded 87 of 281 patients (31%)
rom the original population because they did not meet the inclu-
ion criteria [12].
. Ulcerative colitis
The evolution of the concept of endoscopic score is particularly
vident in UC because the role of the endoscopic activity in dis-
ase management has long been recognized. Numerous scores have
een used for the assessment of endoscopic activity in UC, and a
ecent systematic review identified 31 scoring systems proposed in
he literature [13]. Among these, very few were constantly utilized
n clinical trials. Early in 1937, Bargen et al. described the impor-
ance of directly evaluating the mucosa of patients with ulcerative
olitis using a rigid proctoscope in conjunction with a magnifying
ttachment [14], but the first endoscopic score to evaluate disease
ctivity in UC patients in a clinical trial was proposed by Truelove
nd Witts in 1955 [15]. In 1964, Baron et al. developed a score
o evaluate the appearance of rectosigmoid mucosa using a rigid
roctoscope, in which disease activity was expressed by severity
f bleeding and friability without considering ulcerations [16]. The
aron score was modified by Feagan et al., in 2005, with the removal
f the qualitative assessment of different levels of bleeding, and
he inclusion of ulceration in the evaluation [17]. Baron score has
epresented for a long time the most frequently used endoscopic
core in clinical trials. Its modified version represents a simple and
fficacious tool to evaluate endoscopic activity, but the lack of anr Disease 48 (2016) 703–708
appropriate validation and the unclear definition of MH may limit
the utilization of the score in the future.
In 1987, Schroeder et al. described an instrument to measure
disease activity called the Mayo score, which included both endo-
scopic and clinical items [18]. The part of this composite score
that evaluate endoscopic activity, namely the Mayo endoscopic
subscore (MES), is the scoring system most widely used in clini-
cal trials to describe endoscopic activity as easily reproducible. It
is characterized by 4 components and scores range from 0 to 3,
with 0 indicating inactive disease with normal mucosa; 1 indicating
mild disease (erythema and mild friability); 2 indicating moder-
ate disease (marked erythema, friability, absent vascular pattern
and erosions); and 3 indicating severe disease (spontaneous bleed-
ing and diffuse ulceration). MH  was defined as a MES  of 0 or 1,
which predicts a better outcome than a MES  of 2 or 3 with an
associated reduction in colectomy. MES  has been used in multiple
clinical trials [13]. Its main limitations are the fact that the def-
inition of MH,  although commonly used, has not been validated,
and as mentioned above, recent data suggest a difference progno-
stic relevance between the scores of 0 and 1 [7]. Moreover, the
score does not discriminate between superficial and deep ulcera-
tions, and grades 1 and 2 may  present significant overlap. Osada
et al. found adequate inter- and intra-observer agreement from the
experts, but agreement was markedly lower when trainees were
involved in the scoring [19]. More recently, the suboptimal agree-
ment of the score was  confirmed, and surprisingly, the agreement
coefficient was higher among non-expert than expert gastroen-
terologists (kappa = 0.71 vs. 0.53, respectively) [20].
The need for a better definition of endoscopic activity and the
lack of a fully validated tool have recently led to the proposal of
new indexes in an attempt to increased inter-observer agreement.
In 2012, Travis et al. proposed the Ulcerative Colitis Endoscopic
Index of Severity (UCEIS) [21], and, in a subsequent study, the
authors evaluated the reliability of the UCEIS and validated it with
an independent cohort of investigators [22]. The UCEIS score rep-
resents a validated index of endoscopic severity of UC,  and it is
considered a useful tool in clinical practice for reducing variations
between different observers. However, it has several limitations. As
for other indexes, the definition of MH  remains unclear. In addition,
the thresholds for mild to moderate and severe disease have not
been completely validated. Only the most severely affected part of
the mucosa is scored, meaning that disease extension is not eval-
uated. Most importantly, even though the score offers a detailed
description of mucosal inflammation, a real advantage in the inter-
observer agreement over simpler scores, such as Baron and MES,
has yet to be demonstrated [12].
In an attempt to include disease extension and to increase
inter-observer agreement, the Ulcerative Colitis Colonoscopic
Index of Severity (UCCIS) was recently proposed [23]. The score
shows significant correlation with the clinical indexes, laboratory
measurement of active disease, and good correlation with patient-
defined remission. Therefore, the UCCIS may  represent a useful
tool based on the evaluation of each colonic segment that pro-
vides reproducible results in endoscopic scoring of patients with
UC. However, such a score presents some limitations. First, the orig-
inal study for the development of the score was  a single-center
study of only 50 patients, and larger studies are needed to vali-
date the usefulness of this index. Second, calculating the score
requires a total colonoscopy, which is a more expensive and inva-
sive procedure that is less well tolerated by the patient compared
to sigmoidoscopy. Moreover, UCCIS is pretty more complex com-
paring with other scores and therefore its widespread utilization in
every endoscopic center may not be feasible.
Very recently, to conjugate the simplicity of the MES  with the
need to evaluate disease extension, a Modified Mayo Endoscopic
Score (MMES) was  proposed [24]. Lobaton et al. calculated this new
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Table  1
Most frequently used and more recently proposed endoscopic scores in UC.
Score [year] Calculation Pro Contra
Modified Baron Index
[2005]
Stepwise 5 grade scale:
Normal mucosa (0)
granular with an abnormal vascular
pattern (1)
friable (2)
microulcerations with spontaneous
bleeding (3)
gross ulceration (4)
Easy in clinical practice
Require only rectosigmoidoscopy
Not validated
No definition of MH
Not considering disease extension
Low agreement for granularity and
erythema
Mayo  endoscopic subscore
(MES) [1987]
Stepwise 4 grade scale:
Normal (0): no inflammatory signs
Mild (1): erythema
Moderate (2): friability, erosions
Severe (3): spontaneous bleeding,
ulcerations
Easy in clinical practice
Prospective study
Most used in clinical practice and
clinical trials
Require only rectosigmoidoscopy
Overlap grade 1–2
Low interobserver agreement
Not considering disease extension
Definition of MH questionable
Ulcerative Colitis
Endoscopic Index of
severity (UCEIS) [2012]
Total score (3–11) from the sum of 3
components:
Vascular pattern: normal (1), patchy
obliteration (2), obliterated (3)
Bleeding: none (1), mucosal (2),
luminal mild (3), luminal
moderate-severe (4)
Lesions: none (1), erosions (2),
superficial ulcer (3), deep ulcer (4)
Validated
High interobserver reproducibility
Require only rectosigmoidoscopy
No definition of MH
Not considering disease extension
No established thresholds for mild,
moderate
and severe disease
Definition of superficial vs. deep ulcer
Ulcerative Colitis
Colonoscopic Index of
severity (UCCIS) [2013]
Total score (0–162) = 3.1 × (sum of A in
5  tracts) + 3.6 × (sum of B) + 3.5 × (sum
of  C) + 2.5 × (sum of D)
(A) Vascular pattern: normal (0),
partially visible (1), complete loss (2)
(B)  Granularity: normal (0), fine (1),
coarse (2)
(C) Lesions: none (0), erosions or
pinpoint ulcers (1), numerous shallow
ulcers (2), deep ulcer (3), diffuse
ulceration (4)
(D) Friability/bleeding: none (0),
friability (1), spontaneous bleeding (2)
Consider disease extension
Significant correlation with clinical
index and laboratory tests
Significant interobserver agreement
Not validated in a different casistic
Single center study (only 50 patients)
Requires total colonoscopy
No definition of MH
No established thresholds for mild,
moderate and severe disease
Modified Mayo Endoscopic
Score (MMES) [2015]
Total score = (sum of MES  in 5
tracts) × disease extent (dm)/no. of
segment with active inflammation
(MES ≥ 1)
Consider disease extension
Easy in clinical practice
Significant correlation with clinical
index, laboratory tests and histology
Comp
Not validated in a different casistic
Inter-observer agreement not assessed
No established thresholds for mild,
moderate and severe disease
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core by multiplying the sum of the MES  values of the 5 colonic
egments (rectum, sigmoid, descending, transverse, and ascending
olon) by the total extension of inflammation (in decimeters – dm)
nd dividing that by the number of segments with active inflam-
ation (MES ≥ 1). The MMES  showed significant correlation with
ecal calprotectin (r = 0.73), clinical index (r = 0.54), and histologic
core (r = 0.62). Because of its simplicity and correlation with dif-
erent parameters of disease activity, the MMES  is a promising and
easible tool not only in trials but even in clinical practice. However,
onsidering that MMES  has been just very recently developed, fur-
her studies are needed to better assess the validity of the score (i.e.,
nter-observer agreement was not assessed yet) and its potential
pplication in UC patients.
The most frequently used and more recently developed scores
n UC are summarized in Table 1.
The importance of the ongoing problem of endoscopic evalua-
ion of UC is highlighted by the fact that, despite the first scores
ating back to the 1950s, new scores have been proposed in the
ast 2–3 years. On the one hand, this has led to the attempt of
 more homogenous definition for patients with inactive disease
mucosal healing) by synthesizing the best features of the most
requently used scores (Mayo and Baron) in the development of
he UCEIS score. On the other hand, there is a renewed focus on thelete colonoscopy not essential
challenge of evaluating disease extension. Most of the currently
used scores in UC calculate only the activity of the most inflamed
colonic segment (generally rectum/sigma) to enable the calcula-
tion of the score from recto-sigmoidoscopy. This could have a
concrete advantage of avoiding a complete colonoscopy, which
is a more expensive and time-consuming procedure that could
be inappropriate in specific situations (i.e., severe flares). How-
ever, the extent of mucosal inflammation is clearly one of the
most important factors to determine disease course [1], and not
including disease extension in the endoscopic score may  be a lim-
itation. If the score considers only a segment of colon, patients
with completely different clinical situations, such as severe proc-
titis and severe pancolitis, may have the same endoscopic score.
Moreover, a score determined by evaluating only the most affected
tract may  not reflect the possible progression of the disease in
proximal areas (possible in up to 50% of patients [25]) because the
numeric score would not change. Finally, the possibility of patchy
healing of the colon in treated UC has been highlighted [26,27].
The limitations of an assessment of disease activity based only
on a sigmoidoscopy have recently been highlighted by a retro-
spective analysis of 545 colonoscopic evaluations of UC patients
in which the most inflamed segment was found proximal to the
splenic flexure in 27% of cases. Severe activity (Mayo endoscopic
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Table  2
Most frequently used endoscopic scores in CD.
Score [year] Calculation Pro Contra
CDEIS [1989] Total score (0–44) = sum of 5 segments
score*/no. of explored
segments + ulcerated stenosis (yes = 3,
no = 0) + non-ulcerated stenosis
(yes = 3, no = 0)
*segment score from the sum of:
deep ulceration (yes = 12, no = 0)
superficial ulceration (yes = 6, no = 0)
surface involved (0–10)
surface ulcerated (0–10)
Gold standard
Validated
Prospective study
Extensively applied in clinical trials
Complexity
No definition of MH
No correlation with CDAI
SES-CD [2004] Total score (0–56) = sum of 5 segments
score including the sum of:
Ulcer: none(0), 0.1–0.5 cm(1),
0.5–2 cm(2), >2 cm(3)
Ulcerated surface: none(0), <10%(1),
10–30%(2), >30%(3)
Affected surface: none(0), <50%(1),
50–75%(2), >75%(3)
Narrowing: none(0), single passable(1),
multiple passable(2), unpassable(3)
Validated
Prospective study
Simpler than CDEIS
Correlated with CDEIS
No definition of MH
No correlation with CDAI
Less applied in clinical trials
Rutgeerts [1990] Stepwise 5 grade scale:
I0 – no lesions in neo-terminal ileum
I1 – <5 aphthous lesions in
neo-terminal ileum
I2 – >5 aphthous lesions with normal
mucosa, skip areas with larger lesions,
anastomotic lesions
I3 – diffuse aphthous ileitis
Prospective study
Extensively applied in clinical trials
Strong prognostic relevance
No formal validation
Only in post-operative ileo-colonic
resection
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nodules and/or stenosis
bbreviations: MH = mucosal healing; CDAI = Crohn’s disease activity index.
core = 3) was more frequently found in proximal than in distal seg-
ents, and 40% of patients with inflamed mucosa in the proximal
racts had no inflammation in the rectum-sigmoid colon [28]. Our
roup has recently reported that the UCEIS calculated as a sum
f 5 colonic segments (total UCEIS – tU) performed better than
he regular UCEIS in term of correlation with clinical index and
rognostic value [29]. Considering the relevance of the issue, the
ost recently proposed indexes, namely the UCCIS and the MMES,
nclude the assessment of disease extension in their calculation,
ut the debate is still open [30]. It is noteworthy that, despite the
roposal of different scores, the reproducibility optimization still
emains an unmet goal in the evaluation of endoscopic activity in
C patients, probably due to the intrinsic nature of the disease.
. Crohn’s Disease
As previously mentioned, the endoscopic evaluation of CD has
any challenges. It is well known that symptoms may  not corre-
ate with the activity of disease as measured by endoscopic and
ross-sectional imaging techniques [31], and the clinical Crohn’s
isease Activity Index (CDAI) still represent the reference param-
ter in clinical trials for disease activity assessment. However, the
eed to overcome a simply symptom-based approach and the rel-
vance of intestinal healing as a therapeutic end-point affect the
anagement of CD patients as well, and validated endoscopic
cores have been developed for this purpose. A recent systematic
eview identified 9 endoscopic scores for CD [32]. Among these,
wo had undergone an appropriate validation process [33,34], and
he Rutgeerts score [35], represents a widely used tool in the post-
perative setting, despite its lack of formal validation.The first validated endoscopic evaluative score for CD sever-
ty is the Crohn’s Disease Endoscopic Index of Severity (CDEIS),
resented by the Groupe D’Etudes Therapeutiques Des Affec-
ions Inflammatoires due Tube Digestif (GETAID) in 1989 in amultiphase and prospective study [33]. In the first development
phase, two  endoscopists simultaneously evaluated colonoscopies
from 75 patients, with one endoscopist observing the other dur-
ing the procedure. The calculation of the total score (range 0–44)
was derived from a formula that included the presence of deep or
superficial ulceration, the extent of ulcerated and inflamed mucosa,
and the presence of ulcerated and non-ulcerated stenosis, in 5 ileo-
colonic segments (rectum, sigmoid/left, transverse, right colon and
ileum). A limitation of this approach could be fact that the two
endoscopists scored the items while physically present in the same
procedure room, therefore limiting the independence of the obser-
vations. Furthermore, segments that were not evaluated because of
technical difficulties, anastomotic narrowing, or surgery were not
considered for these calculations even though they could represent
important aspects. In terms of the validation phase, a recent study
reported that a central reading of the CDEIS to assess CD severity by
a group of 4 readers had excellent intra- and inter-observer reliabil-
ity (intra-observer ICC, 0.89; 95% confidence interval [CI], 0.86–0.93
and inter-observer ICC, 0.71; 95% CI, 0.61–0.79) [32]. Potential lim-
itations include no stated definition of MH  and the fact that the
CDEIS does not correlate with CDAI [36]. Moreover, the complex-
ity of the calculation is the real limitation to the widespread use
of the score. However, the CDEIS still represent the gold standard
for endoscopic activity evaluation in CD. In fact, the CDEIS has been
used as an inclusion criterion in some studies and as end-point in
several clinical trials [32].
In 2004, to simplify the complexity of CDEIS, Daperno et al.
used a prospective study to develop the Simple Endoscopic Score
in Crohn’s Disease (SES-CD) [34]. The four parameters of the CDEIS
with high inter-observer agreement were adopted in the SES-CD:
ulcer size, proportion of surface covered by the ulcer, proportion of
surface covered by other lesions and luminal stenosis. Each descrip-
tor was  graded in a stepwise manner, and the total score was
calculated as the sum of all the items in each segment, with a range
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f 0 to 56. Agreement for the items was again assessed by two endo-
copists who graded 71 colonoscopies, resulting in inter-observer
CCs for the SES-CD and CDEIS of 0.98 and 0.90, respectively. As in
he CDEIS validation, the agreement phase was determined by two
ndoscopists who evaluated the same procedure simultaneously.
lthough the endoscopists scored the colonoscopy without com-
unicating, they may  have been influenced by one another. In
erms of the validation phase, Khanna et al. reported that a cen-
ral reading of the SES-CD by a group of 4 readers to assess CD
everity had very good intra- and inter-observer reliability (intra-
bserver ICC, 0.89; 95% CI, 0.86–0.93 and inter-observer ICC, 0.71;
5% CI, 0.63–0.76) [37]. The SES-CD simplified index was  highly
orrelated with the CDEIS (Spearman’s r = 0.883), and this corre-
ation became almost perfect when both scales were scored by a
ingle endoscopist (Spearman’s r = 0.938, p < 0.0001) [38]. The rela-
ionship between score and disease activity has not been clearly
efined; however, two studies [39,40] have proposed a correla-
ion between scoring and inflammation [remission (0–2), mild
nflammation (3–6), moderate inflammation (7–16) and severe
nflammation (>16)]. Because of the high degree of correlation
etween the CDEIS and the simplicity of its application, the SES-CD
as been used in clinical trials [32] and may  even be implemented
n clinical practice. In the CDEIS, no clear definition for MH  has been
rovided.
One of the most frequently used endoscopic scores is the
utgeerts score for postoperative CD recurrence. It was  formally
eveloped 1990 by examining 89 patients with ileal resection
or CD and observing clinical outcomes in patients with early
eoterminal ileum lesions. A 5-grade stepwise numeric index was
eveloped for the gradation of endoscopic postoperative recur-
ence in the neo-terminal ileum. Patients with lower scores had
 better prognosis than those with more severe endoscopic lesions
35]. Although the score have been used in both trials and clinical
ractice, only a few very recent studies have explored intra- and
nter-observer agreement, which opens the door to a formal vali-
ation [41,42]. For its consistent correlation with prognosis, the
utgeerts score is the best example of the application of a clinical
core to the concrete management of patients, and in the specific
ubset of post-operative patients, it is probably the most obvious
onfirmation of the role of MH in disease outcome. For that reason,
he score has recently been included in a clinical trial that repre-
ent the first treat-to-target study in which endoscopic activity has
een considered a primary end-point for decision-making (POCER)
43]. Moreover, it has been used extensively to determine efficacy
n clinical trials in post-operative CD patients [32].
Table 2 summarizes the most commonly used endoscopic scores
n CD.
. Conclusion
The challenge of endoscopic evaluation of disease activity in
BD is far from solved. In UC, several different scores have been
roposed, but not one has been definitely adopted as the ‘gold
tandard’ for endoscopic activity evaluation. In CD, the importance
f the endoscopic evaluation has only recently been highlighted.
he application of endoscopic scores has been strongly influenced
n the last decade by the increasing relevance of the MH as an
mportant end-point for the management of IBD. In addition to
he current limitations and the over-estimation of the MH concept,
he key relevance of the endoscopic evaluation for IBD assessment
nd management has been underlined in recent years. Conse-
uently, both old and new challenges relative to the application
f endoscopic scores are being considered and evaluated exten-
ively. Available data indicating that the current methods available
o evaluate endoscopic disease activity are sub-optimal are
[r Disease 48 (2016) 703–708 707
increasing rapidly, and the same MH  does not yet have a universally
accepted definition. Because the widespread use of central read-
ers to improve the quality and agreement of endoscopic reports
is not feasible, a concrete solution appears to be the implementa-
tion of efficient scores that may  reduce variability and improve the
quality of endoscopic reports. To accomplish this, a more intense
commitment by scientific societies to implement correct utiliza-
tion of endoscopic scores is desirable. The education and training
of endoscopists could lead to consistent improvements in the inter-
observer agreement and reproducibility of the endoscopic reports,
as recently shown in the preliminary results of an Italian endo-
scopic educational program [44]. In the longer term, the progress
of available tools (i.e., high-definition endoscopes), may  contribute
to a more accurate definition of endoscopic activity, as indicated
by a preliminary study [45]. Moreover, the wider availability of
multimedia tools in the endoscopic room will probably lead to the
utilization and transfer of video for a more complete evaluation of
endoscopic activity in IBD patients.
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